samedan logo
 
 
 
spacer
home > ebr > summer 2007 > from idea to market: four top tips
PUBLICATIONS
European Biopharmaceutical Review

From Idea to Market: Four Top Tips

Susannah Adams at Critchleys Chartered Accountants writes that when it comes to approaching potential investors, biopharmaceutical companies must present innovative and inventive ideas, and with adequate information to support them

Statistics show that the UK biopharmaceutical industry is booming. On May 6th, Malcolm Wicks, the UK’s Minister of State for Science and Innovation, announced that biopharmaceuticals are projected to rise to account for approximately 30 per cent of the global pharmaceutical market by 2015. Nowhere is this boom more resonant than in the UK, one of the top three centres worldwide for biopharmaceutical research. In 2005, one quarter of all European pharmaceutical R&D investment was focused in the UK, and a third of all European biotech floats also occurred here.

One particular success story has been the anti-rheumatism drug Humira®, the first product originating from the UK biotechnology sector to achieve ‘blockbuster’ status – achieving sales of $1.4 billion within two years of its launch. At the smaller end of the spectrum, university spinouts have led to swift development and commercialisation in all areas of technology, including the biopharmaceutical market. In two years’ time, the first ever university spinout, Oxford Instruments, will celebrate its 50th anniversary. In addition, many geographical regions have local investment networks which provide an effective interface between the high technology entrepreneur and investor.

In the Winter 2006 edition of EBR, Eileen Modral outlined the vital role played by Business Angel Networks (BANs) in providing mentoring and bridging the ‘equity gap’ faced by many young biotech companies. Each network has members willing to invest between £25,000 and £1 million – this can be a crucial source of matched funding for Government-sponsored growth and capital funds.

The harsh realities of raising seed or development capital from a private investor are well known. Simply having a good idea isn’t enough – not having a business plan or a grasp of the turnover and profit in the first year will lose an investor’s interest at a stroke. This is a problem faced by many young companies looking to attract investment in an innovative market; getting their message across effectively can be very difficult. This dilemma is not new. For centuries, innovators have had to ‘sell’ their ideas to wealthy backers, and ‘private equity’ as a concept began in the 18th century. A particularly famous example is the business collaboration between the talented, but impecunious, James Watt and the wealthy industrialist Matthew Boulton in the production of the steam engine.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Susannah Adams is Assistant Director of Corporate Finance at Critchleys Chartered Accountants in Oxford. She has over six years’ experience in raising finance for businesses at all stages of development. She sits on the panel for Oxford Early Investments, advising companies on ways to improve the impact of their presentations. She graduated in English from St Anne’s College, Oxford, and has a keen interest in the growth of the biotech industry.
spacer
Susannah Adams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement